Zobrazeno 1 - 10
of 145
pro vyhledávání: '"R. J. Simes"'
Autor:
P. L. Thompson, J. Hui, J. Beilby, L. J. Palmer, G. F. Watts, M. J. West, A. Kirby, S. Marschner, R. J. Simes, D. R. Sullivan, H. D. White, R. Stewart, A. M. Tonkin
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background It is unclear whether genetic variants identified from single nucleotide polymorphisms (SNPs) strongly associated with coronary heart disease (CHD) in genome-wide association studies (GWAS), or a genetic risk score (GRS) derived f
Externí odkaz:
https://doaj.org/article/96fab9ee494749348d0580cefb62476e
Autor:
Monica Tang, Thomas John, R. J. Simes, Sallie-Anne Pearson, Craig R. Lewis, Chee Khoon Lee, Andrea L Schaffer
Publikováno v:
Journal of Geriatric Oncology. 12:930-936
Objectives Older adults constitute the majority of patients with lung cancer. However, they are under-represented in clinical trials as eligibility criteria often restrict enrolment based on comorbidities that are common with aging. We aimed to descr
Autor:
Andrea L Schaffer, Benjamin Daniels, R. J. Simes, Sallie-Anne Pearson, Chee Khoon Lee, Monica Tang, Belinda E Kiely
Publikováno v:
Breast Cancer Research and Treatment. 187:893-902
Cardiac function assessment is important for detecting and managing trastuzumab-associated cardiotoxicity. Our study estimates rates and predictors of cardiac assessment among patients receiving trastuzumab for HER2-positive early breast cancer (HER2
Autor:
Andrea L Schaffer, Monica Tang, Benjamin Daniels, R. J. Simes, Belinda E Kiely, Sallie-Anne Pearson, Chee Khoon Lee
Publikováno v:
British Journal of Cancer
Background Randomised clinical trials (RCTs) demonstrate that trastuzumab improves survival in patients with human epidermal growth factor 2-positive early breast cancer (HER2 + EBC), but real-world patients and clinical practice often differ from RC
Autor:
Heikki Joensuu, Sonia Yip, Timothy J. Price, Monica Tang, R. J. Simes, John Zalcberg, Wendy Hague, Katrin Marie Sjoquist
Publikováno v:
British Journal of Cancer
International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or sp
Autor:
R. J. Simes, Julia Chen, Matthew Links, Monica Tang, Ian C. Marschner, David Goldstein, Chee Khoon Lee, Sarah J. Lord
Publikováno v:
Pancreas. 48(10)
Objectives We evaluated how well phase II trials in locally advanced and metastatic pancreatic cancer (LAMPC) meet current recommendations for trial design. Methods We conducted a systematic review of phase II first-line treatment trial for LAMPC. We
Autor:
G. Dickie, David I. Watson, Euan Walpole, Janine Thomas, R. Bohmer, Rebecca Mercieca-Bebber, Elizabeth H Barnes, Tao Mai, David Cameron, Kate Wilson, M. Burge, Stephen P. Ackland, John Zalcberg, Z. Samoon, T. Wang, J. Leung, Andrew Barbour, R. J. Simes, Mark Smithers, Val Gebski
Publikováno v:
Annals of Oncology. 31:S903-S904
Autor:
Stephen P. Ackland, Michael D. Green, John F. Forbes, Haryana M. Dhillon, S Tees, Val Gebski, G. Van Hazel, Nicholas Zdenkowski, Alan S. Coates, R. J. Simes, A Wilson, John A. Levi
Publikováno v:
Breast cancer research and treatment. 176(2)
The separate impacts of dose and dose intensity of chemotherapy for metastatic breast cancer remain uncertain. The primary objective of this trial was to compare a short, high-dose, intensive course of epirubicin and cyclophosphamide (EC) with a long
Autor:
R. J. Simes, Lisa M. Askie, Ivy W Jiang, Kylie E Hunter, Anna Lene Seidler, Aidan Christopher Tan
Publikováno v:
Journal of Clinical Epidemiology
Objectives The objective of this study was to determine the prevalence of trial registration in health research, whether trial registration status and timing vary depending on trial characteristics, and the relationship between trial registration sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2be6e5864679248b233a19487374a39
https://hdl.handle.net/2123/24719
https://hdl.handle.net/2123/24719
Publikováno v:
JNCI Cancer Spectrum
Background We sought to compare the effect sizes hypothesized in the trial design, observed in the trial results, and considered clinically meaningful by the American Society of Clinical Oncology (ASCO) 2014 recommendations, in phase III trials of ta